User menu

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Bibliographic reference Smolen, Josef S ; Breedveld, Ferdinand C ; Burmester, Gerd R ; Bykerk, Vivian ; Dougados, Maxime ; et. al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.. In: Annals of the Rheumatic Diseases, Vol. 75, no.1, p. 3-15 (2016)
Permanent URL http://hdl.handle.net/2078.1/172487
  1. Nasonov E. L., Karateev D. E., Does Russia need a treat-to-target initiative?, 10.1093/rheumatology/keu156
  2. Goekoop-Ruiterman Yvonne P.M., Comparison of Treatment Strategies in Early Rheumatoid Arthritis : A Randomized Trial, 10.7326/0003-4819-146-6-200703200-00005
  3. Nam J L, Villeneuve E, Hensor E M A, Wakefield R J, Conaghan P G, Green M J, Gough A, Quinn M, Reece R, Cox S R, Buch M H, van der Heijde D M, Emery P, A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial, 10.1136/annrheumdis-2013-204882
  4. Nam J L, Villeneuve E, Hensor E M A, Conaghan P G, Keen H I, Buch M H, Gough A K, Green M J, Helliwell P S, Keenan A M, Morgan A W, Quinn M, Reece R, van der Heijde D M, Wakefield R J, Emery P, Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study), 10.1136/annrheumdis-2013-203440
  5. Heimans L, Wevers-de Boer K V C, Visser K, Goekoop R J, van Oosterhout M, Harbers J B, Bijkerk C, Speyer I, de Buck M P D M, de Sonnaville P B J, Grillet B A M, Huizinga T W J, Allaart C F, A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study, 10.1136/annrheumdis-2013-203243
  6. Allaart, Clin Exp Rheumatol, 31, S14 (2013)
  7. Woodburn James, Hennessy Kym, Steultjens Martijn PM, McInnes Iain B, Turner Deborah E, Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in earlyrheumatoid arthritis?, 10.1186/1757-1146-3-8
  8. Bakker Marije F., Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis : A Randomized Trial, 10.7326/0003-4819-156-5-201203060-00004
  9. Putrik Polina, Ramiro Sofia, Kvien Tore K, Sokka Tuulikki, Uhlig Till, Boonen Annelies, Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?, 10.1136/annrheumdis-2013-203819
  10. Putrik Polina, Ramiro Sofia, Kvien Tore K, Sokka Tuulikki, Pavlova Milena, Uhlig Till, Boonen Annelies, , Inequities in access to biologic and synthetic DMARDs across 46 European countries, 10.1136/annrheumdis-2012-202603
  11. Dougados M, EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees, 10.1136/ard.2004.023697
  12. de Wit M. P. T., Smolen J. S., Gossec L., van der Heijde D. M. F. M., Treating rheumatoid arthritis to target: the patient version of the international recommendations, 10.1136/ard.2010.146662
  13. Viller, J Rheumatol, 26, 2114 (1999)
  14. Fraenkel, Arthritis Care Res (Hoboken), 64, 977 (2012)
  15. Goodacre L. J., Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication, 10.1093/rheumatology/keh116
  16. Contreras-Yáñez Irazú, Cabiedes Javier, Rull-Gabayet Marina, Pascual-Ramos Virginia, Ponce De León Sergio, Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic Drugs, 10.1097/maj.0b013e3181e8bcb0
  17. ten Wolde S., Breedveld F.C., Dijkmans B.A.C., Hermans J., Vandenbroucke J.P., van de Laar M.A.F.J., Markusse H.M., Janssen M., van den Brink H.R., Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis, 10.1016/s0140-6736(96)90535-8
  18. Smolen Josef S, van der Heijde Désirée, Machold Klaus P, Aletaha Daniel, Landewé Robert, Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1, 10.1136/annrheumdis-2013-204317
  19. Fautrel B., Gandjbakhch F., Foltz V., Pham T., Morel J., Alfaiate T., Dernis E., Gaudin P., Mariette X., Tubach F., OP0066 Targeting the Lowest Efficacious Dose for Rheumatoid Arthritis Patients in Remission: Clinical and Structural Impact of a Step-Down Strategy Trial Based on Progressive Spacing of TNF-Blocker Injections (Strass Trial), 10.1136/annrheumdis-2013-eular.271
  20. Smolen Josef S, Emery Paul, Fleischmann Roy, van Vollenhoven Ronald F, Pavelka Karel, Durez Patrick, Guérette Benoît, Kupper Hartmut, Redden Laura, Arora Vipin, Kavanaugh Arthur, Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial, 10.1016/s0140-6736(13)61751-1
  21. Emery, Ann Rheum Dis, 72, 399 (2013)
  22. van der Woude D., Visser K., Klarenbeek N. B., Ronday H. K., Peeters A. J., Kerstens P. J. S. M., Dijkmans B. A. C., Huizinga T. W. J., van der Helm-van Mil A. H. M., Allaart C. F., Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies, 10.1093/rheumatology/ker516
  23. Tanaka, Clin Exp Rheumatol, 31, S22 (2013)
  24. Saleem B., Keen H., Goeb V., Parmar R., Nizam S., Hensor E. M. A., Churchman S. M., Quinn M., Wakefield R., Conaghan P. G., Ponchel F., Emery P., Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?, 10.1136/ard.2009.117341
  25. Tanaka Yoshiya, Hirata Shintaro, Kubo Satoshi, Fukuyo Shunsuke, Hanami Kentaro, Sawamukai Norifumi, Nakano Kazuhisa, Nakayamada Shingo, Yamaoka Kunihiro, Sawamura Fusae, Saito Kazuyoshi, Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study, 10.1136/annrheumdis-2013-204016
  26. Tanaka Y., Takeuchi T., Mimori T., Saito K., Nawata M., Kameda H., Nojima T., Miyasaka N., Koike T., , Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study, 10.1136/ard.2009.121491
  27. Takeuchi T., Matsubara T., Ohta S., Mukai M., Amano K., Tohma S., Tanaka Y., Yamanaka H., Miyasaka N., Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan, 10.1093/rheumatology/keu338
  28. Smolen Josef S, Nash Peter, Durez Patrick, Hall Stephen, Ilivanova Elena, Irazoque-Palazuelos Fedra, Miranda Pedro, Park Min-Chan, Pavelka Karel, Pedersen Ronald, Szumski Annette, Hammond Constance, Koenig Andrew S, Vlahos Bonnie, Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial, 10.1016/s0140-6736(12)61811-x
  29. Molenaar Esmeralda T. H., Voskuyl Alexandre E., Dinant Huib J., Bezemer P. Dick, Boers Maarten, Dijkmans Ben A. C., Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission, 10.1002/art.11481
  30. Aletaha D., Funovits J., Breedveld F. C., Sharp J., Segurado O., Smolen J. S., Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment, 10.1002/art.24433
  31. Soubrier M., Puechal X., Sibilia J., Mariette X., Meyer O., Combe B., Flipo R. M., Mulleman D., Berenbaum F., Zarnitsky C., Schaeverbeke T., Fardellone P., Dougados M., Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial, 10.1093/rheumatology/kep261
  32. VAN DER HEIJDE D., KEYSTONE E. C., CURTIS J. R., LANDEWE R. B., SCHIFF M. H., KHANNA D., KVIEN T. K., IONESCU L., GERVITZ L. M., DAVIES O. R., LUIJTENS K., FURST D. E., Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial, 10.3899/jrheum.111171
  33. Aletaha Daniel, Funovits Julia, Keystone Edward C., Smolen Josef S., Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients, 10.1002/art.22943
  34. van den Hoek J., Roorda L. D., Boshuizen H. C., van Hees J., Rupp I., Tijhuis G. J., Dekker J., van den Bos G. A. M., Long-Term Physical Functioning and Its Association With Somatic Comorbidity and Comorbid Depression in Patients With Established Rheumatoid Arthritis: A Longitudinal Study : Comorbidity and Long-Term Physical Functioning in RA, 10.1002/acr.21950
  35. Radner H., Smolen J. S., Aletaha D., Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis, 10.1093/rheumatology/keq334
  36. Radner H., Smolen J. S., Aletaha D., Impact of comorbidity on physical function in patients with rheumatoid arthritis, 10.1136/ard.2009.118430
  37. Aletaha D., Funovits J., Smolen J. S., Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction, 10.1136/ard.2010.138693
  38. Koller M. D., Aletaha D., Funovits J., Pangan A., Baker D., Smolen J. S., Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients, 10.1093/rheumatology/kep291
  39. Bathon, J Rheumatol, 33, 234 (2006)
  40. Tutuncu Z, Reed G, Kremer J, Kavanaugh A, Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?, 10.1136/ard.2005.051144
  41. Westlake S. L., Colebatch A. N., Baird J., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, 10.1093/rheumatology/kep366
  42. Choi Hyon K, Hernán Miguel A, Seeger John D, Robins James M, Wolfe Frederick, Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, 10.1016/s0140-6736(02)08213-2
  43. Westlake S. L., Colebatch A. N., Baird J., Curzen N., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, 10.1093/rheumatology/keq316
  44. Simard Julia F., Neovius Martin, Askling Johan, , Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: Drug-specific comparisons in the Swedish Biologics Register, 10.1002/art.34582
  45. Listing Joachim, Kekow Jörn, Manger Bernhard, Burmester Gerd-Rüdiger, Pattloch Dagmar, Zink Angela, Strangfeld Anja, Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab, 10.1136/annrheumdis-2013-204021
  46. Navarro-Compan, Rheumatology (2014)
  47. Curtis, Arthritis Rheum, 65, S186 (2013)
  48. Pincus Theodore, Swearingen Christopher J., Bergman Martin, Yazici Yusuf, RAPID3 (Routine Assessment of Patient Index Data 3), a Rheumatoid Arthritis Index Without Formal Joint Counts for Routine Care: Proposed Severity Categories Compared to Disease Activity Score and Clinical Disease Activity Index Categories, 10.3899/jrheum.080182
  49. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien T K, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen J S, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D, Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations, 10.1136/ard.2008.091454
  50. Klarenbeek N. B., Guler-Yuksel M., van der Heijde D. M. F. M., Hulsmans H. M. J., Kerstens P. J. S. M., Molenaar T. H. E., de Sonnaville P. B. J., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab, 10.1136/ard.2010.131201
  51. Smolen Josef S., Van Der Heijde Désirée M. F. M., St.Clair E. William, Emery Paul, Bathon Joan M., Keystone Edward, Maini Ravinder N., Kalden Joachim R., Schiff Michael, Baker Daniel, Han Chenglong, Han John, Bala Mohan, , Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial, 10.1002/art.21678
  52. van Leeuwen, J Rheumatol, 21, 425 (1994)
  53. VAN DER HEIJDE D. M. F. M., VAN RIEL P. L. C. M., VAN LEEUWEN M. A., VAN'T HOF M. A., VAN RIJSWIJK M. H., VAN DE PUTTE L. B. A., PROGNOSTIC FACTORS FOR RADIOGRAPHIC DAMAGE AND PHYSICAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS. A PROSPECTIVE FOLLOW-UP STUDY OF 147 PATIENTS, 10.1093/rheumatology/31.8.519
  54. Food and Drug Administration. Guidance for Industry—Rheumatoid arthritis: Developing drug products for treatment. Draft Gudance May 2013. http://www.fdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM354468pdf (accessed 5 Oct 2013).
  55. Fleischmann, Ann Rheum Dis (2014)
  56. Kavanaugh Arthur, Fleischmann Roy M, Emery Paul, Kupper Hartmut, Redden Laura, Guerette Benoit, Santra Sourav, Smolen Josef S, Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study, 10.1136/annrheumdis-2011-201247
  57. Bakker, Ann Rheum Dis, 66, iii56 (2007)
  58. Aletaha Daniel, Ward Michael M., Machold Klaus P., Nell Valerie P. K., Stamm Tanja, Smolen Josef S., Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states, 10.1002/art.21235
  59. Smolen J. S., Wollenhaupt J., Durez P., Gomez-Reino J., Grassi W., Le Bars M., Gaillez C., Poncet C., Westhovens R., FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial, 10.1136/annrheumdis-2013-eular.1369
  60. Mierau M., Schoels M., Gonda G., Fuchs J., Aletaha D., Smolen J. S., Assessing remission in clinical practice, 10.1093/rheumatology/kem007
  61. Koevoets, Arthritis Rheum, 60, 957 (2009)
  62. Radner, Arthritis Rheum, 64, S1104 (2012)
  63. Aletaha Daniel, Smolen Josef S., Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints, 10.1002/art.30634
  64. Smolen Josef S., Aletaha Daniel, Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants, 10.1002/art.27740
  65. van der Heijde D, Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results, 10.1136/ard.2004.034371
  66. Makinen H, Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?, 10.1136/ard.2005.037333
  67. Aletaha Daniel, Smolen Josef S., The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases, 10.1016/j.rdc.2005.09.005
  68. van der Heijde Désirée, Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?, 10.1136/annrheumdis-2011-200797
  69. Wakefield Richard J, D'Agostino Maria Antonietta, Naredo Esperanza, Buch Maya H, Iagnocco Annamaria, Terslev Lene, Ostergaard Mikkel, Backhaus Marina, Grassi Walter, Dougados Maxime, Burmester Gerd R, Saleem Benazir, de Miguel Eugenio, Estrach Cristina, Ikeda Kei, Gutierrez Marwin, Thompson Robert, Balint Peter, Emery Paul, After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1, 10.1136/annrheumdis-2011-201048
  70. Gärtner Miriam, Mandl Peter, Radner Helga, Supp Gabriela, Machold Klaus P., Aletaha Daniel, Smolen Josef S., Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission : Sonographic Versus Clinical Joint Assessment in RA, 10.1002/art.38016
  71. van Tuyl Lilian H. D., Felson David T., Wells George, Smolen Josef, Zhang Bin, Boers Maarten, , , Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review, 10.1002/acr.20021
  72. Stucki Gerold, Cieza Alarcos, Geyh Szilvia, Battistella Linamara, Lloyd Jill, Symmons Deborah, Kostanjsek Nenad, Schouten Jan, ICF Core Sets for rheumatoid arthritis, 10.1080/16501960410015470
  73. Grønning Kjersti, Rødevand Erik, Steinsbekk Aslak, Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis, 10.1007/s10067-010-1534-z
  74. Sakellariou Garifallia, Scirè Carlo Alberto, Verstappen Suzanne M M, Montecucco Carlomaurizio, Caporali Roberto, In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis, 10.1136/annrheumdis-2012-201817
  75. Balsa A., de Miguel E., Castillo C., Peiteado D., Martin-Mola E., Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard, 10.1093/rheumatology/kep442
  76. Provan S. A., Semb A. G., Hisdal J., Stranden E., Agewall S., Dagfinrud H., Angel K., Atar D., Kvien T. K., Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study, 10.1136/ard.2010.141523
  77. Thiele Katja, Huscher Dörte, Bischoff Sascha, Späthling-Mestekemper Susanna, Backhaus Marina, Aringer Martin, Kohlmann Thomas, Zink Angela, , Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis, 10.1136/annrheumdis-2012-201821
  78. Dale, Arthritis Rheum, 65, S338 (2013)
  79. Dougados Maxime, Devauchelle-Pensec Valérie, Ferlet Jean françois, Jousse-Joulin sandrine, D'Agostino Maria-Antonietta, Backhaus Marina, Bentin Jacques, Chalès Gérard, Chary-Valckenaere Isabelle, Conaghan Philip, Wakefield Richard J, Etcheparre Frédéric, Gaudin Philippe, Grassi Walter, Heijde Désirée van der, Mariette Xavier, Naredo Esperanza, Szkudlarek Marcin, The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound, 10.1136/annrheumdis-2012-201469
  80. Pope Janet E., Haraoui Boulos, Rampakakis Emmanouil, Psaradellis Eliofotisti, Thorne Carter, Sampalis John S., , Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial : Usual Care vs. Treating to a Target in Established RA With Adalimumab, 10.1002/acr.22010
  81. Gullick N. J., Oakley S. P., Zain A., Gibson T., Jones T., Mistlin A., Rees J. D., Panayi G. S., Kirkham B. W., Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years, 10.1093/rheumatology/ker399
  82. Soubrier M., Lukas C., Sibilia J., Fautrel B., Roux F., Gossec L., Patternotte S., Dougados M., Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort, 10.1136/ard.2010.137695
  83. Goekoop-Ruiterman Y P M, de Vries-Bouwstra J K, Kerstens P J S M, Nielen M M J, Vos K, van Schaardenburg D, Speyer I, Seys P E H, Breedveld F C, Allaart C F, Dijkmans B A C, DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis, 10.1136/ard.2008.097683
  84. Schipper Lydia G, Vermeer Marloes, Kuper Hillechiena H, Hoekstra Monique O, Haagsma Cees J, Broeder Alfons A Den, Riel Piet van, Fransen Jaap, van de Laar Mart AFJ, A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry, 10.1136/annrheumdis-2011-200274
  85. van Eijk I. C., Nielen M. M. J., van der Horst-Bruinsma I., Tijhuis G. J., Boers M., Dijkmans B. A. C., van Schaardenburg D., Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial, 10.1093/rheumatology/ker355
  86. Schoels M., Knevel R., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D. T., Burmester G., Combe B., Cutolo M., Dougados M., Emery P., van der Heijde D., Huizinga T. W. J., Kalden J., Keystone E. C., Kvien T. K., Martin-Mola E., Montecucco C., de Wit M., Smolen J. S., Evidence for treating rheumatoid arthritis to target: results of a systematic literature search, 10.1136/ard.2009.123976
  87. Stoffer, Ann Rheum Dis (2015)
  88. Haraoui B., Smolen J. S., Aletaha D., Breedveld F. C., Burmester G., Codreanu C., Da Silva J. P., de Wit M., Dougados M., Durez P., Emery P., Fonseca J. E., Gibofsky A., Gomez-Reino J., Graninger W., Hamuryudan V., Jannaut Pe{eta with perispomeni}a M. J., Kalden J., Kvien T. K., Laurindo I., Martin-Mola E., Montecucco C., Santos Moreno P., Pavelka K., Poor G., Cardiel M. H., Stanislawska-Biernat E., Takeuchi T., van der Heijde D., , Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire, 10.1136/ard.2011.154179
  89. Waimann Christian, Arthritis Rheum, 66, S1037 (2014)
  90. Solomon Daniel H., Bitton Asaf, Katz Jeffrey N., Radner Helga, Brown Erika M., Fraenkel Liana, Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis? : Treat to Target in RA, 10.1002/art.38323
  91. Porter Duncan, Dale James, Sattar Naveed, How low to aim in rheumatoid arthritis? Learning from other disciplines, 10.1136/annrheumdis-2013-204339
  92. Felson D. T., Smolen J. S., Wells G., Zhang B., van Tuyl L. H. D., Funovits J., Aletaha D., Allaart C. F., Bathon J., Bombardieri S., Brooks P., Brown A., Matucci-Cerinic M., Choi H., Combe B., de Wit M., Dougados M., Emery P., Furst D., Gomez-Reino J., Hawker G., Keystone E., Khanna D., Kirwan J., Kvien T. K., Landewe R., Listing J., Michaud K., Martin-Mola E., Montie P., Pincus T., Richards P., Siegel J. N., Simon L. S., Sokka T., Strand V., Tugwell P., Tyndall A., van der Heijde D., Verstappen S., White B., Wolfe F., Zink A., Boers M., American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials, 10.1136/ard.2011.149765
  93. LINDE L., SORENSEN J., OSTERGAARD M., HORSLEV-PETERSEN K., HETLAND M. L., Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?, 10.3899/jrheum.090898
  94. Radner Helga, Smolen Josef S, Aletaha Daniel, Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs, 10.1186/ar4491
  95. Klarenbeek N. B., Koevoets R., van der Heijde D. M. F. M., Gerards A. H., ten Wolde S., Kerstens P. J. S. M., Huizinga T. W. J., Dijkmans B. A. C., Allaart C. F., Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis, 10.1136/ard.2010.149260
  96. Cardiel Mario H., Díaz-Borjón Alejandro, Vázquez del Mercado Espinosa Mónica, Gámez-Nava Jorge Iván, Barile Fabris Leonor A., Pacheco Tena César, Silveira Torre Luis H., Pascual Ramos Virginia, Goycochea Robles María Victoria, Aguilar Arreola Jorge Enrique, González Díaz Verónica, Álvarez Nemegyei José, González-López Laura del Carmen, Salazar Páramo Mario, Portela Hernández Margarita, Castro Colín Zully, Xibillé Friedman Daniel Xavier, Álvarez Hernández Everardo, Casasola Vargas Julio, Cortés Hernández Miguel, Flores-Alvarado Diana E., Martínez Martínez Laura A., Vega-Morales David, Flores-Suárez Luis Felipe, Medrano Ramírez Gabriel, Barrera Cruz Antonio, García González Adolfo, López López Susana Marisela, Rosete Reyes Alejandra, Espinosa Morales Rolando, Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología, 10.1016/j.reuma.2013.10.006
  97. Wollenhaupt J., Albrecht K., Krüger K., Müller-Ladner U., The new 2012 German recommendations for treating rheumatoid arthritis : Differences compared to the European standpoint, 10.1007/s00393-012-1093-6
  98. Smolen Josef S, Landewé Robert, Breedveld Ferdinand C, Buch Maya, Burmester Gerd, Dougados Maxime, Emery Paul, Gaujoux-Viala Cécile, Gossec Laure, Nam Jackie, Ramiro Sofia, Winthrop Kevin, de Wit Maarten, Aletaha Daniel, Betteridge Neil, Bijlsma Johannes W J, Boers Maarten, Buttgereit Frank, Combe Bernard, Cutolo Maurizio, Damjanov Nemanja, Hazes Johanna M W, Kouloumas Marios, Kvien Tore K, Mariette Xavier, Pavelka Karel, van Riel Piet L C M, Rubbert-Roth Andrea, Scholte-Voshaar Marieke, Scott David L, Sokka-Isler Tuulikki, Wong John B, van der Heijde Désirée, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, 10.1136/annrheumdis-2013-204573
  99. Smolen J. S., Landewe R., Breedveld F. C., Dougados M., Emery P., Gaujoux-Viala C., Gorter S., Knevel R., Nam J., Schoels M., Aletaha D., Buch M., Gossec L., Huizinga T., Bijlsma J. W. J. W., Burmester G., Combe B., Cutolo M., Gabay C., Gomez-Reino J., Kouloumas M., Kvien T. K., Martin-Mola E., McInnes I., Pavelka K., van Riel P., Scholte M., Scott D. L., Sokka T., Valesini G., van Vollenhoven R., Winthrop K. L., Wong J., Zink A., van der Heijde D., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 10.1136/ard.2009.126532
  100. Singh Jasvinder A., Furst Daniel E., Bharat Aseem, Curtis Jeffrey R., Kavanaugh Arthur F., Kremer Joel M., Moreland Larry W., O'Dell James, Winthrop Kevin L., Beukelman Timothy, Bridges S. Louis, Chatham W. Winn, Paulus Harold E., Suarez-almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M., Leong Amye L., Matteson Eric L., Schousboe John T., Moynihan Eileen, Kolba Karen S., Jain Archana, Volkmann Elizabeth R., Agrawal Harsh, Bae Sangmee, Mudano Amy S., Patkar Nivedita M., Saag Kenneth G., 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis : 2012 ACR RA Treatment Recommendations, 10.1002/acr.21641
  101. Smolen J. S., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J. J., Haraoui B., Kalden J., Keystone E. C., Kvien T. K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D., , Treating rheumatoid arthritis to target: recommendations of an international task force, 10.1136/ard.2009.123919
  102. Vermeer Marloes, Kuper Hillechiena H, Bernelot Moens Hein J, Hoekstra Monique, Posthumus Marcel D, van Riel Piet LCM, van de Laar Mart AFJ, Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort, 10.1186/ar4099
  103. Verstappen S M M, Jacobs J W G, van der Veen M J, Heurkens A H M, Schenk Y, ter Borg E J, Blaauw A A M, Bijlsma J W J, , Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial), 10.1136/ard.2007.071092
  104. Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Porter Duncan, Kincaid Wilma, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, 10.1016/s0140-6736(04)16676-2
  105. Van Ede Annelies E., Laan Roland F. J. M., Rood Maarten J., Huizinga Tom W. J., Van De Laar Mart A. F. J., Denderen Christiaan J. Van, Westgeest Toon A. A., Romme Ton C., De Rooij Dirk-Jan R. A. M., Jacobs Marike J. M., De Boo Theo M., Van Der Wilt Gert-Jan, Severens Johan L., Hartman Margriet, Krabbe Paul F. M., Dijkmans Ben A. C., Breedveld Ferdinand C., Van De Putte Leo B. A., Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study, 10.1002/1529-0131(200107)44:7<1515::aid-art273>3.0.co;2-7
  106. Visser K, van der Heijde D, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, 10.1136/ard.2008.092668
  107. Pincus, Clin Exp Rheumatol, 21, S178 (2003)
  108. Lukas C., van der Heijde D., Fatenajad S., Landewe R., Repair of erosions occurs almost exclusively in damaged joints without swelling, 10.1136/ard.2009.119156
  109. Smolen J S, Han C, van der Heijde D M F M, Emery P, Bathon J M, Keystone E, Maini R N, Kalden J R, Aletaha D, Baker D, Han J, Bala M, St Clair E W, , Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade, 10.1136/ard.2008.090019
  110. Luukkainen R, Kajander A, Isomaki H, Treatment of rheumatoid arthritis., 10.1136/bmj.2.6150.1501-c
  111. Emery P, Salmon M, Early rheumatoid arthritis: time to aim for remission?, 10.1136/ard.54.12.944
  112. Nell V. P. K., Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, 10.1093/rheumatology/keh199
  113. Lard Leroy R, Visser Henk, Speyer Irene, vander Horst-Bruinsma Irene E, Zwinderman Aeilko H, Breedveld Ferdinand C, Hazes Johanna M.W, Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies, 10.1016/s0002-9343(01)00872-5
  114. van der Heide Agnes, The Effectiveness of Early Treatment with “Second-Line” Antirheumatic Drugs : A Randomized, Controlled Trial, 10.7326/0003-4819-124-8-199604150-00001
  115. Aletaha Daniel, Nell Valerie PK, Stamm Tanja, Uffmann Martin, Pflugbeil Stephan, Machold Klaus, Smolen Josef S, 10.1186/ar1740
  116. Felson David T., Anderson Jennifer J., Boers Maarten, Bombardier Claire, Furst Daniel, Goldsmith Charles, Katz Linda M., Lightfoot Robert, Paulus Harold, Strand Vibeke, Tugwell Peter, Weinblatt Michael, James Williams H., Wolfe Frederick, Kieszak Stephanie, American college of rheumatology preliminary definition of improvement in rheumatoid arthritis, 10.1002/art.1780380602
  117. Smolen J. S., Breedveld F. C., Schiff M. H., Kalden J. R., Emery P., Eberl G., van Riel P. L., Tugwell P., A simplified disease activity index for rheumatoid arthritis for use in clinical practice, 10.1093/rheumatology/keg072
  118. Prevoo M. L. L., Van'T Hof M. A., Kuper H. H., Van Leeuwen M. A., Van De Putte L. B. A., Van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis : MODIFIED DISEASE ACTIVITY SCORE, 10.1002/art.1780380107
  119. Van der Heijde, J Rheumatol, 20, 579 (1993)